Serious adverse events and liver‐related morbidity: incidence of gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of bleeding from gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oesophageal variceal bleeding · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes oesophageal variceal bleeding compared with no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Global state: clinically important change in global state · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes global state: clinically important change assessed by: number of… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review
Cognitive functioning: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: clinically important adverse effectsassessed by: number of participants with a delayed memory deficitStudy duration: 4 weeks · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes adverse effects: clinically important adverse effectsassessed by:… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review
Quality of life: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social functioning: clinically important change ‐ not measured · people with the acute phase of schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropout · people with the acute phase of schizophrenia
It is very uncertain whether magnetic seizure therapy plus standard care changes leaving the study early: any reasonassessed by: number of dropouts… compared with electroconvulsive therapy plus standard care (very low certainty).
1 finding from 1 review
Oral candidiasis prevalence · Children and adolescents (<18 years) living with HIV (CLWH)
Oral candidiasis prevalence fell significantly after cART compared with before cART in the same children (very low certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in any adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with radiotherapy showed no clear difference in progression‐free survival Median compared with radiotherapy alone (low certainty).
1 finding from 1 review
Tumour‐free actuarial survival at 5 years · women with locally advanced cervical cancer
1 finding from 1 review